For research use only. Not for therapeutic Use.
THZ1（Cat No.:I018064）is a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), an enzyme crucial for transcription regulation and cell cycle control through its role in activating RNA polymerase II. By inhibiting CDK7, THZ1 blocks transcriptional initiation and elongation, leading to the downregulation of oncogenes and inducing apoptosis in cancer cells, particularly those with high transcriptional activity. THZ1 has shown potent antitumor effects in various cancers, including neuroblastoma, leukemia, and solid tumors. Its selective targeting of CDK7 makes it a promising candidate for developing transcription-based cancer therapies.
| Catalog Number | I018064 |
| CAS Number | 1604811-14-4 |
| Molecular Formula | C₅₂H₆₅ClN₁₂O₈S |
| Purity | ≥95% |
| IUPAC Name | 4-[[(E)-4-[3-[2-[2-[2-[2-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]ethoxy]ethoxy]ethoxy]ethylcarbamoylamino]propyl-methylamino]but-2-enoyl]amino]-N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]benzamide |
| InChI | InChI=1S/C52H65ClN12O8S/c1-65(24-8-20-55-51(69)56-22-26-72-28-30-73-29-27-71-25-21-54-45(66)14-5-4-13-44-48-43(34-74-44)62-52(70)64-48)23-7-15-46(67)59-36-18-16-35(17-19-36)49(68)60-37-9-6-10-38(31-37)61-50-58-33-41(53)47(63-50)40-32-57-42-12-3-2-11-39(40)42/h2-3,6-7,9-12,15-19,31-33,43-44,48,57H,4-5,8,13-14,20-30,34H2,1H3,(H,54,66)(H,59,67)(H,60,68)(H2,55,56,69)(H,58,61,63)(H2,62,64,70)/b15-7+/t43-,44-,48-/m0/s1 |
| InChIKey | ARPCJVVFIKPHFA-SFDVBDGFSA-N |
| SMILES | CN(CCCNC(=O)NCCOCCOCCOCCNC(=O)CCCC[C@H]1[C@@H]2[C@H](CS1)NC(=O)N2)C/C=C/C(=O)NC3=CC=C(C=C3)C(=O)NC4=CC=CC(=C4)NC5=NC=C(C(=N5)C6=CNC7=CC=CC=C76)Cl |
| Reference | [1]. Kwiatkowski N, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20. |
